Cargando…
4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency
[Image: see text] CYP51 is a P450 enzyme involved in the biosynthesis of the sterol components of eukaryotic cell membranes. CYP51 inhibitors have been developed to treat infections caused by fungi, and more recently the protozoan parasite Trypanosoma cruzi, the causative agent of Chagas disease. To...
Autores principales: | Calvet, Claudia M., Vieira, Debora F., Choi, Jun Yong, Kellar, Danielle, Cameron, Michael D., Siqueira-Neto, Jair Lage, Gut, Jiri, Johnston, Jonathan B., Lin, Li, Khan, Susan, McKerrow, James H., Roush, William R., Podust, Larissa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148169/ https://www.ncbi.nlm.nih.gov/pubmed/25101801 http://dx.doi.org/10.1021/jm500448u |
Ejemplares similares
-
Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based
Inhibitors Targeting Trypanosoma cruzi CYP51
por: Vieira, Debora F., et al.
Publicado: (2014) -
4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
por: Calvet, Claudia Magalhaes, et al.
Publicado: (2017) -
Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
por: Gunatilleke, Shamila S., et al.
Publicado: (2012) -
Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010) -
Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit
por: Chen, Chiung-Kuang, et al.
Publicado: (2009)